company background image
XVIVO logo

Xvivo Perfusion OM:XVIVO Stock Report

Last Price

SEK 451.50

Market Cap

SEK 14.2b

7D

-0.8%

1Y

70.7%

Updated

22 Nov, 2024

Data

Company Financials +

Xvivo Perfusion AB (publ)

OM:XVIVO Stock Report

Market Cap: SEK 14.2b

XVIVO Stock Overview

A medical technology company, develops and markets machines and perfusion solutions for assessing usable organs and maintains in optimal condition pending transplantation in Sweden, the United States, the Netherlands, Italy, North and South America, Europe, the Middle East, Africa, the Asia Pacific, and Oceania. More details

XVIVO fundamental analysis
Snowflake Score
Valuation2/6
Future Growth5/6
Past Performance4/6
Financial Health6/6
Dividends0/6

Xvivo Perfusion AB (publ) Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Xvivo Perfusion
Historical stock prices
Current Share PriceSEK 451.50
52 Week HighSEK 547.00
52 Week LowSEK 252.50
Beta2.13
11 Month Change-7.48%
3 Month Change-15.29%
1 Year Change70.70%
33 Year Change64.48%
5 Year Change165.59%
Change since IPO2,276.32%

Recent News & Updates

Xvivo Perfusion (STO:XVIVO) Is Posting Healthy Earnings, But It Is Not All Good News

Nov 04
Xvivo Perfusion (STO:XVIVO) Is Posting Healthy Earnings, But It Is Not All Good News

Results: Xvivo Perfusion AB (publ) Beat Earnings Expectations And Analysts Now Have New Forecasts

Oct 27
Results: Xvivo Perfusion AB (publ) Beat Earnings Expectations And Analysts Now Have New Forecasts

Recent updates

Xvivo Perfusion (STO:XVIVO) Is Posting Healthy Earnings, But It Is Not All Good News

Nov 04
Xvivo Perfusion (STO:XVIVO) Is Posting Healthy Earnings, But It Is Not All Good News

Results: Xvivo Perfusion AB (publ) Beat Earnings Expectations And Analysts Now Have New Forecasts

Oct 27
Results: Xvivo Perfusion AB (publ) Beat Earnings Expectations And Analysts Now Have New Forecasts

With Xvivo Perfusion AB (publ) (STO:XVIVO) It Looks Like You'll Get What You Pay For

Oct 25
With Xvivo Perfusion AB (publ) (STO:XVIVO) It Looks Like You'll Get What You Pay For

Is There An Opportunity With Xvivo Perfusion AB (publ)'s (STO:XVIVO) 40% Undervaluation?

Aug 03
Is There An Opportunity With Xvivo Perfusion AB (publ)'s (STO:XVIVO) 40% Undervaluation?

Xvivo Perfusion AB (publ) (STO:XVIVO) Stock Rockets 34% As Investors Are Less Pessimistic Than Expected

Apr 25
Xvivo Perfusion AB (publ) (STO:XVIVO) Stock Rockets 34% As Investors Are Less Pessimistic Than Expected

There Are Reasons To Feel Uneasy About Xvivo Perfusion's (STO:XVIVO) Returns On Capital

Apr 11
There Are Reasons To Feel Uneasy About Xvivo Perfusion's (STO:XVIVO) Returns On Capital

Need To Know: Analysts Just Made A Substantial Cut To Their Xvivo Perfusion AB (publ) (STO:XVIVO) Estimates

Feb 05
Need To Know: Analysts Just Made A Substantial Cut To Their Xvivo Perfusion AB (publ) (STO:XVIVO) Estimates

We Think That There Are Issues Underlying Xvivo Perfusion's (STO:XVIVO) Earnings

Feb 01
We Think That There Are Issues Underlying Xvivo Perfusion's (STO:XVIVO) Earnings

Earnings Beat: Xvivo Perfusion AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Jan 28
Earnings Beat: Xvivo Perfusion AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Returns On Capital At Xvivo Perfusion (STO:XVIVO) Have Stalled

Aug 24
Returns On Capital At Xvivo Perfusion (STO:XVIVO) Have Stalled

Why Xvivo Perfusion AB (publ) (STO:XVIVO) Could Be Worth Watching

Jul 17
Why Xvivo Perfusion AB (publ) (STO:XVIVO) Could Be Worth Watching

Do Xvivo Perfusion's (STO:XVIVO) Earnings Warrant Your Attention?

Jun 16
Do Xvivo Perfusion's (STO:XVIVO) Earnings Warrant Your Attention?

Xvivo Perfusion (STO:XVIVO) May Have Issues Allocating Its Capital

Apr 19
Xvivo Perfusion (STO:XVIVO) May Have Issues Allocating Its Capital

Are Investors Undervaluing Xvivo Perfusion AB (publ) (STO:XVIVO) By 21%?

Mar 23
Are Investors Undervaluing Xvivo Perfusion AB (publ) (STO:XVIVO) By 21%?

With EPS Growth And More, Xvivo Perfusion (STO:XVIVO) Makes An Interesting Case

Mar 07
With EPS Growth And More, Xvivo Perfusion (STO:XVIVO) Makes An Interesting Case

When Should You Buy Xvivo Perfusion AB (publ) (STO:XVIVO)?

Feb 13
When Should You Buy Xvivo Perfusion AB (publ) (STO:XVIVO)?

Be Wary Of Xvivo Perfusion (STO:XVIVO) And Its Returns On Capital

Dec 14
Be Wary Of Xvivo Perfusion (STO:XVIVO) And Its Returns On Capital

Is There An Opportunity With Xvivo Perfusion AB (publ)'s (STO:XVIVO) 35% Undervaluation?

Nov 17
Is There An Opportunity With Xvivo Perfusion AB (publ)'s (STO:XVIVO) 35% Undervaluation?

Xvivo Perfusion (STO:XVIVO) Might Be Having Difficulty Using Its Capital Effectively

Aug 20
Xvivo Perfusion (STO:XVIVO) Might Be Having Difficulty Using Its Capital Effectively

Statutory Profit Doesn't Reflect How Good Xvivo Perfusion's (STO:XVIVO) Earnings Are

Jul 21
Statutory Profit Doesn't Reflect How Good Xvivo Perfusion's (STO:XVIVO) Earnings Are

Be Wary Of Xvivo Perfusion (STO:XVIVO) And Its Returns On Capital

Mar 30
Be Wary Of Xvivo Perfusion (STO:XVIVO) And Its Returns On Capital

At kr258, Is Xvivo Perfusion AB (publ) (STO:XVIVO) Worth Looking At Closely?

Feb 18
At kr258, Is Xvivo Perfusion AB (publ) (STO:XVIVO) Worth Looking At Closely?

A Look At The Fair Value Of Xvivo Perfusion AB (publ) (STO:XVIVO)

Jan 30
A Look At The Fair Value Of Xvivo Perfusion AB (publ) (STO:XVIVO)

Shareholder Returns

XVIVOSE Medical EquipmentSE Market
7D-0.8%-5.8%-2.4%
1Y70.7%-7.8%10.9%

Return vs Industry: XVIVO exceeded the Swedish Medical Equipment industry which returned -7.8% over the past year.

Return vs Market: XVIVO exceeded the Swedish Market which returned 10.9% over the past year.

Price Volatility

Is XVIVO's price volatile compared to industry and market?
XVIVO volatility
XVIVO Average Weekly Movement4.6%
Medical Equipment Industry Average Movement7.3%
Market Average Movement5.5%
10% most volatile stocks in SE Market11.2%
10% least volatile stocks in SE Market3.3%

Stable Share Price: XVIVO has not had significant price volatility in the past 3 months compared to the Swedish market.

Volatility Over Time: XVIVO's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1998161Christoffer Rosenbladwww.xvivogroup.com

Xvivo Perfusion AB (publ), a medical technology company, develops and markets machines and perfusion solutions for assessing usable organs and maintains in optimal condition pending transplantation in Sweden, the United States, the Netherlands, Italy, North and South America, Europe, the Middle East, Africa, the Asia Pacific, and Oceania. The company offers Kidney Assist Transport, a portable device that allows hypothermic pulsatile perfusion of donor kidneys with oxygenated solution for up to 24 hours; Liver Assist that provides clinicians a choice of perfusion protocols whether hypothermic, normothermic, sub-normothermic, or a combination; XVIVO System (XPS), a comprehensive ex vivo lung perfusion (EVLP) platform that offers an overview of the entire process; and STEEN Solution, a buffered extracellular solution intended for the assessment of isolated lungs after removal from the donor in preparation for eventual transplantation into a recipient. It also provides Perfadex Plus, an extracellular, low potassium, dextran-based electrolyte preservation solution; XPS Disposable Lung Kit that contains all the necessary devices and tubing to run a normothermic EVLP procedure on the XPS; XVIVO Organ Chamber, a sterile single-use container intended to be used as a temporary receptacle for isolated donor lungs; and XVIVO Lung Cannula Set, a sterile single-use set that connects isolated donor lungs to an extracorporeal perfusion system for ex-vivo assessment.

Xvivo Perfusion AB (publ) Fundamentals Summary

How do Xvivo Perfusion's earnings and revenue compare to its market cap?
XVIVO fundamental statistics
Market capSEK 14.22b
Earnings (TTM)SEK 204.27m
Revenue (TTM)SEK 750.59m

69.6x

P/E Ratio

18.9x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
XVIVO income statement (TTM)
RevenueSEK 750.59m
Cost of RevenueSEK 192.08m
Gross ProfitSEK 558.52m
Other ExpensesSEK 354.25m
EarningsSEK 204.27m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

Jan 28, 2025

Earnings per share (EPS)6.48
Gross Margin74.41%
Net Profit Margin27.21%
Debt/Equity Ratio0%

How did XVIVO perform over the long term?

See historical performance and comparison